Xenon Pharmaceuticals Inc (NASDAQ: XENE) kicked off on Monday, down -6.07% from the previous trading day, before settling in for the closing price of $44.49. Over the past 52 weeks, XENE has traded in a range of $26.74-$46.60.
Annual sales at Healthcare sector company slipped by -14.28% over the past five years. While this was happening, its average annual earnings per share was recorded -40.92%. With a float of $74.76 million, this company’s outstanding shares have now reached $77.12 million.
Xenon Pharmaceuticals Inc (XENE) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Xenon Pharmaceuticals Inc is 3.26%, while institutional ownership is 106.70%. The most recent insider transaction that took place on Jan 02 ’26, was worth 1,777,093. In this transaction PRESIDENT & CEO of this company sold 40,000 shares at a rate of $44.43, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Jan 02 ’26, when Company’s Officer proposed sale 40,000 for $44.43, making the entire transaction worth $1,777,166.
Xenon Pharmaceuticals Inc (XENE) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.84 earnings per share (EPS), higher than consensus estimate (set at -0.84) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -40.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.47% during the next five years compared to -14.28% drop over the previous five years of trading.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Take a look at Xenon Pharmaceuticals Inc’s (XENE) current performance indicators. Last quarter, stock had a quick ratio of 12.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 430.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.88, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.59 in one year’s time.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc (NASDAQ: XENE) saw its 5-day average volume 1.01 million, a negative change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 36.38%.
During the past 100 days, Xenon Pharmaceuticals Inc’s (XENE) raw stochastic average was set at 56.27%, which indicates a significant increase from 7.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.43 in the past 14 days, which was higher than the 1.38 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.45, while its 200-day Moving Average is $36.65. Nevertheless, the first resistance level for the watch stands at $43.56 in the near term. At $45.33, the stock is likely to face the second major resistance level. The third major resistance level sits at $46.40. If the price goes on to break the first support level at $40.72, it is likely to go to the next support level at $39.65. Assuming the price breaks the second support level, the third support level stands at $37.88.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Key Stats
The company with the Market Capitalisation of 3.23 billion has total of 77,275K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -234,330 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -84,710 K.
